CLAIMS

1. An implant that fits inside the middle meatus and is configured to remain implanted for at least 4 months so as to prevent the need for surgery in a subject with a sinus condition who is a candidate for endoscopic sinus surgery, the implant comprising: (i) a coating comprising over 2000 micrograms of mometasone furoate, and (ii) a topcoat layer, the implant configured to have a zero-order release for at least 60% of the mometasone furoate for a total release duration of more than 12 weeks.

2. An implant according to Claim 1, in which the implant is configured to release 20 to 80% of the mometasone furoate during the first 12 weeks.

3. An implant according to Claim 1, in which the implant is configured to exhibit the zero-order release after week 1.

4. An implant according to Claim 1, in which the sinus condition is chronic.

5. An implant according to Claim 4, in which the sinus condition is characterized by at least two symptoms selected from the group consisting of nasal obstruction, nasal congestion, difficulty breathing through nasal passages, nasal polyp, nasal discharge, loss of smell and facial pain.

6. An implant according to Claim 1, in which the implant comprises up to 5000 micrograms of mometasone furoate.

7. An implant according to Claim 1, in which the implant is a braided structure.

8. An implant according to Claim 1, in which the implant is a tubular structure.

9. An implant according to Claim 1, in which the implant comprises helical strands.

10. An implant according to Claim 1, in which the implant is self-expanding.

11. An implant according to Claim 1, in which the implant has a diameter of at least 13mm.

12. An implant according to Claim 1, in which the implant has a length of at least 10mm.

13. A combination of implants for preventing the need for surgery in a subject who has a sinus condition and is a candidate for endoscopic sinus surgery, comprising

first and second implants, each comprising: (i) at least one drug-containing coating containing over 2000 micrograms of mometasone furoate and (ii) a topcoat layer,

in which the first implant is configured to fit inside a first middle meatus of a patient, the mometasone furoate configured to have a zero-order release for 12 weeks or more of a planned implantation period; and

in which the second implant is configured to fit inside a second middle meatus of the patient, the mometasone furoate configured to have a zero-order release for 12 weeks or more of a planned implantation period,

in which the first and second implants are configured to remain implanted for at least 5 months so as to prevent the need for endoscopic sinus surgery in the subject.

14. A combination of implants according to Claim 13, in which the first and second implants are configured to release 20 to 80% of the mometasone furoate during the first 12 weeks.

15. A combination of implants according to Claim 13, in which the each of the first and second implants is configured to exhibit a zero-order release after week 1.

16. A combination of implants according to Claim 13, in which the sinus condition is a chronic sinus condition.

17. A combination of implants according to Claim 16, in which the sinus condition is characterized by at least two symptoms selected from the group consisting of nasal obstruction, nasal congestion, difficulty breathing through nasal passages, nasal polyp, nasal discharge, loss of smell and facial pain.

18. A combination of implants according to Claim 13, in which at least one of the first or second implants comprises up to 5000 micrograms of mometasone furoate.

19. A combination of implants according to Claim 13, in which at least one of the first or second implants is a braided structure.

20. A combination of implants according to Claim 13, in which at least one of the first or second implants is a tubular structure.

21. A combination of implants according to Claim 13, in which at least one of the first or second implants comprises helical strands.

22. A combination of implants according to Claim 13, in which at least one of the first or second implants is self-expanding.